Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026
Company Deals

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Fineline Cube Apr 12, 2026
Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026
Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Fineline Cube Apr 12, 2026
Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Fineline Cube Apr 12, 2026
Company Drug

AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations

Fineline Cube Apr 1, 2026

AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase...

Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026

Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc....

Company Drug

Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability

Fineline Cube Apr 1, 2026

Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers...

Company Drug

Gan & Lee Pharmaceuticals’ Once-Weekly Insulin GZR4 Demonstrates Superior HbA1c Reduction in Phase III Trials

Fineline Cube Apr 1, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced that two pivotal Phase III clinical studies, SUPER-1...

Company Drug

Abbisko Therapeutics Secures EMA Orphan Drug Designation for Irpagratinib in Hepatocellular Carcinoma

Fineline Cube Apr 1, 2026

Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the European Medicines Agency (EMA) has granted...

Company

MicroPort Scientific Returns to Profitability as Global Access Platform Drives 78.8% Revenue Surge

Fineline Cube Apr 1, 2026

MicroPort Scientific Corp. (HKG: 0853) announced its 2025 full-year financial results, reporting a return to...

Company Medical Device

Amoy Diagnostics and HutchMed Secure World’s First NMPA Approval for MET Amplification Companion Diagnostic

Fineline Cube Mar 31, 2026

Amoy Diagnostics Co., Ltd. (SHE: 300685) and HutchMed (China) Ltd. (NASDAQ: HCM, HKG: 0013) have...

Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026

Abbott (NYSE: ABT) has announced a strategic collaboration with Flatiron Health, a leading oncology health...

Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Fineline Cube Mar 31, 2026

Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I...

Company Medical Device

Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures

Fineline Cube Mar 31, 2026

Boston Scientific (NYSE: BSX) has announced FDA 510(k) clearance for its Asurys Fluid Management System,...

Company Deals

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Fineline Cube Mar 31, 2026

Kailera Therapeutics has announced plans for an initial public offering (IPO) to secure additional funding...

Company Drug

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor

Fineline Cube Mar 31, 2026

Abbisko Therapeutics Co., Ltd. (HKG: 2256) has announced FDA clinical trial approval for its investigational...

Company

Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology/CNS Segment Strength

Fineline Cube Mar 31, 2026

Luye Pharma Group (HKG: 2186) has announced its 2025 financial results, reporting RMB 6.308 billion...

Company

Luye Pharma Subsidiary Boan Bio Reports 8.1% Revenue Growth Driven by Multiple Product Approvals in 2025

Fineline Cube Mar 31, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955), a controlling subsidiary of Luye Pharma Group (HKG:...

Company Drug

ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma

Fineline Cube Mar 31, 2026

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) has announced the first patient dosing in a...

Company Drug

Merck’s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial

Fineline Cube Mar 31, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) has disclosed detailed results from the CORALreef AddOn...

Company Drug

Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels

Fineline Cube Mar 31, 2026

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced FDA marketing approval for Ponlimsi, its biosimilar...

Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) has announced a licensing agreement with...

Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026

AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an...

Medical Device

Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety

Fineline Cube Mar 31, 2026

Roche AG (SWX: ROG, OTCMKTS: RHHBY) has announced the commercial launch of its cobas MPX-E...

Posts pagination

1 … 4 5 6 … 648

Recent updates

  • Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
  • Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
  • Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies
  • Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC
  • Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.